project id: TCGA-BLCA; case submitter id: TCGA-BT-A42B; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 0.51; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.47; rna integrity number: 7.4; age at index: 59; days to birth: -21788; days to death: 534; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Dead; year of birth: 1952; age at diagnosis: 21788; ajcc clinical t: T3b; ajcc pathologic m: MX; ajcc pathologic n: N1; ajcc pathologic stage: Stage IV; ajcc pathologic t: T3a; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 469.0; icd 10 code: C67.2; last known disease status: not reported; morphology: 8130/3; primary diagnosis: Papillary transitional cell carcinoma; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Lateral wall of bladder; synchronous malignancy: No; tissue or organ of origin: Lateral wall of bladder; tumor grade: Not Reported; year of diagnosis: 2011; alcohol history: Not Reported; cigarettes per day: 1.095890410958904; pack years smoked: 20.0; is ffpe: false; composition: Not Reported; days to collection: 316; days to sample procurement: 0; initial weight: 210.0; portion submitter id: TCGA-BT-A42B-01A-32; percent lymphocyte infiltration: 1.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 30.0; percent stromal cells: 0.0; percent tumor cells: 70.0; percent tumor nuclei: 60.0;